Bigtincan Holdings Limited

Equities

BTH

AU000000BTH6

Biotechnology & Medical Research

Market Closed - Australian S.E. 02:10:05 2024-04-29 am EDT 5-day change 1st Jan Change
0.15 AUD 0.00% Intraday chart for Bigtincan Holdings Limited 0.00% -25.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bigtincan Holdings Logs AU$30 Million Revenue in Fiscal Q3; Shares Surge 19% MT
Bigtincan Holdings Limited(ASX:BTH) dropped from S&P/ASX All Ordinaries Index CI
Bigtincan Shares Shed 11% as Fiscal H1 Revenue Contracts 1.5%; Loss Narrows MT
Transcript : Bigtincan Holdings Limited, H1 2024 Earnings Call, Feb 27, 2024
Bigtincan Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Transcript : Bigtincan Holdings Limited - Shareholder/Analyst Call
Bigtincan Holdings Limited Provides Earnings Guidance for the Fiscal Year 2024 CI
Bigtincan Holdings Limited Announces Resignation of Farouk Hussein as Non-Executive Director CI
Bigtincan Holdings Limited(ASX:BTH) dropped from S&P Global BMI Index CI
Bigtincan Reportedly Say It Remains in Takeover Talks CI
Bigtincan Holdings Launches Cost Reduction Program MT
Transcript : Bigtincan Holdings Limited, 2023 Earnings Call, Aug 30, 2023
Bigtincan Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Bigtincan to Borrow AU$15 Million to Grow AI Technology MT
Bigtincan Holdings Limited Provides Financial Results Outlook for Fiscal Year 2023 CI
Transcript : Bigtincan Holdings Limited - Special Call
Bigtincan Holdings Limited Launches GenieAI Technology, Delivering Transformational Sales Productivity Gains to Customers CI
Bigtincan Holdings Limited Provides Earnings Guidance for the Year 2023 CI
Transcript : Bigtincan Holdings Limited, H1 2023 Earnings Call, Feb 27, 2023
Bigtincan Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Bigtincan Appoints Morgan Stanley to Evaluate Interest it Received from Potential Buyers CI
Bigtincan Acquires Revenue Data Capture Platform SalesDirector.ai MT
Bigtincan's New Relationship Intelligence Technology Unlocks Value Hidden in Relationship Networks CI
Bigtincan Holdings to Seek M&A CI
Bigtincan completes capital raising despite suitor SQN Investors' concerns RE
Chart Bigtincan Holdings Limited
More charts
Beta Pharmaceutical Limited is a Australia-based biopharmaceutical company. The Company is focused on the identification, development and commercialization of products and therapies targeting the chemoprevention and treatment of breast cancer. The Company is working in collaboration with scientists at the College of Pharmacy, University of Louisiana at Monroe in southern the United States of America (ULM) to develop cancer chemopreventive agents using natural phytonutrients, called tocotrienols as treatments for breast cancers. Funded by Beta Pharmaceutical Limited, the applied research programme with ULM includes four laboratories and is known as the Breast Cancer and Health Project, which has been underway.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.15 AUD
Average target price
0.39 AUD
Spread / Average Target
+160.00%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. BTH Stock
  4. News Bigtincan Holdings Limited
  5. Bigtincan to Borrow AU$15 Million to Grow AI Technology